New data and considerations for EGFR+ NSCLC management in 2022 (UK BROADCAST)

Learning objective:         

After watching this broadcast, participants should be able to:

• Discuss new data on the management of patients with EGFR-mutant NSCLC
• Evaluate how new data on therapeutic options for EGFR exon 20 insertion mutations in NSCLC will be integrated into clinical practice

 

Scientific Committee:

• Matthew Krebs (UK)
• Antonio Passaro (Italy)

Faculty:

• Natasha Leighl (Canada)
• Alfredo Addeo (Switserland)